Albertsons Companies, Inc. Form 8-K Summary
Business Context and Reporting Period
On August 27, 2025, Albertsons Companies, Inc. (the "Company") filed a Current Report on Form 8-K to disclose the entry into a material definitive agreement. The Company, a Delaware corporation headquartered in Boise, Idaho, entered into a Fifth Amended and Restated Asset-Based Revolving Credit Agreement (the "Restated Credit Agreement") with Bank of America, N.A., as administrative agent, and other lenders.
Key Financial Metrics and Debt Structure
The filing details the restructuring of the Company's senior secured revolving credit facility. Key terms include:
- Total Facility Size: $4.0 billion senior secured revolving credit facility (ABL Facility).
- Subfacilities: Includes a $1.5 billion letter of credit subfacility and a $250 million swingline loan subfacility.
- Expansion Option: The Company may increase commitments by up to the greater of $1.5 billion or the amount by which the borrowing base exceeds current commitments.
- Maturity Date: August 27, 2030.
- Interest Rates:
- Base Rate: Base rate plus a margin ranging from 0.25% to 0.50% based on excess availability.
- Term SOFR: Term SOFR plus a margin ranging from 1.25% to 1.50% based on excess availability.
- Fees: Commitment fee of 0.25% per annum on the average daily unused amount of the ABL Facility.
The filing does not provide specific values for revenue, profit, cash flow, or current liquidity positions, as this report focuses solely on the credit agreement terms.
Material Changes and Borrowing Base
The Restated Credit Agreement replaces the Fourth Amended and Restated Asset-Based Revolving Credit Agreement dated December 20, 2021. The borrowing base is calculated based on eligible assets, including:
- 90% of eligible credit card receivables.
- 90% of eligible pharmacy receivables.
- 85% of the value of eligible prescription files.
- 90% to 92.5% of eligible inventory (non-perishable, pharmacy, and perishable), subject to specific caps.
- Pharmacy Cap: The aggregate portion of the borrowing base attributable to pharmacy scripts and inventory is capped at the lesser of $1 billion or 25% of the borrowing base.
- Perishables Cap: Eligible perishable inventory is capped at 25% of the borrowing base.
Covenants, Risks, and Contingencies
The agreement includes standard affirmative and negative covenants restricting asset dispositions, additional indebtedness, dividends, and mergers. A specific financial covenant is triggered if excess availability falls below 10% of the lesser of aggregate commitments or the borrowing base, or below $250 million. Upon such a trigger, the Company must maintain a fixed charge coverage ratio of 1.0:1.0.
Events of default include nonpayment, covenant breaches, cross-defaults, bankruptcy, and change of control. Obligations are secured by a first-priority lien on substantially all assets of the Company and its guarantors.
Investor Verification Checklist
- Verify the current utilization rate of the $4.0 billion facility to assess immediate liquidity needs.
- Review the Company's most recent financial statements to calculate the current fixed charge coverage ratio in case the excess availability trigger is active.
- Confirm the composition of the borrowing base, specifically the valuation of eligible pharmacy scripts and inventory, given the specific caps applied to these categories.
- Monitor the Company's ability to maintain excess availability above the $250 million threshold to avoid the imposition of the fixed charge coverage ratio covenant.